CG Invites Co., Ltd. (KOSDAQ:083790)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,527.00
+44.00 (2.97%)
Apr 1, 2026, 3:30 PM KST
Market Cap117.42B -36.0%
Revenue (ttm)27.39B +277.6%
Net Income-3.52B
EPS-46.00
Shares Out76.89M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume158,951
Average Volume217,943
Open1,519.00
Previous Close1,483.00
Day's Range1,495.00 - 1,565.00
52-Week Range1,171.00 - 2,300.00
Beta0.24
RSI54.21
Earnings DateApr 2, 2026

About CG Invites

CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The compan... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 105
Stock Exchange KOSDAQ
Ticker Symbol 083790
Full Company Profile

Financial Performance

In 2025, CG Invites's revenue was 27.39 billion, an increase of 277.64% compared to the previous year's 7.25 billion. Losses were -3.52 billion, -93.17% less than in 2024.

Financial Statements